Patents by Inventor Crystal L. Mackall
Crystal L. Mackall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240139320Abstract: The present disclosure generally relates to, inter alia, chimeric antigen receptors (CARs) that contain an intracellular signaling domain without an immune receptor tyrosine based activation motif (ITAM). The disclosure also provides compositions and methods useful for producing such molecules, as well as methods for the detection and treatment of diseases, such as cancer.Type: ApplicationFiled: February 23, 2022Publication date: May 2, 2024Inventors: Robbie G. Majzner, Aidan Tousley, Louai Labanieh, Crystal L. Mackall, Maria Caterina Rotiroti
-
Publication number: 20240084007Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: ApplicationFiled: November 6, 2023Publication date: March 14, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Rimas J. Orentas, Ira H. Pastan, Dimiter S. Dimitrov, Crystal L. MacKall
-
Publication number: 20240084008Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: ApplicationFiled: November 6, 2023Publication date: March 14, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Rimas J. Orentas, Ira H. Pastan, Dimiter S. Dimitrov, Crystal L. MacKall
-
Patent number: 11807682Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: GrantFiled: May 8, 2020Date of Patent: November 7, 2023Assignee: The United States of America, as represented by the Secretary, Department of Heath and Human ServicesInventors: Rimas J. Orentas, Ira H. Pastan, Dimiter S. Dimitrov, Crystal L. Mackall
-
Publication number: 20230348559Abstract: The present disclosure relates generally to polypeptide constructs, and particularly relate to T-cell receptor (TCR) constructs having binding affinity for a specific cognate antigen. The disclosure also provides compositions and methods useful for producing such constructs as well as methods for the diagnosis, prevention, and/or treatment of conditions associated with cells expressing the cognate antigen recognized by the polypeptide constructs.Type: ApplicationFiled: April 23, 2021Publication date: November 2, 2023Inventors: Diane TSENG, Mark M. DAVIS, Crystal L. MACKALL, Shin-Heng CHIOU
-
Publication number: 20230248824Abstract: The present disclosure generally relates to, inter alia, recombinant immune cells that have been engineered to express elevated levels of one or more glucose transporters, and particularly relate to engineered immune cells exhibiting increased glycolytic flux and/or enhanced effector functions. Also provided are methods for generating a population of engineered immune cells with enhanced effector function, pharmaceutical compositions the same, as well as methods and kits for the prevention and/or treatment of a health condition in subjects in need thereof.Type: ApplicationFiled: July 8, 2021Publication date: August 10, 2023Inventors: Dorota Danuta KLYSZ, Crystal L. MACKALL
-
Publication number: 20230183312Abstract: Disclosed are chimeric antigen receptors comprising a CD2 co-stimulatory domain that retain function against CD58? and CD58low tumor cells, and CD2 co-stimulatory receptors that promote CAR function against CD58? and CD58low tumor cells.Type: ApplicationFiled: February 12, 2021Publication date: June 15, 2023Inventors: Robbie G. MAJZNER, Crystal L. MACKALL, Aidan TOUSLEY, Michelle MONJE-DEISSEROTH, Louai LABANIEH, Christopher MOUNT
-
Publication number: 20230110875Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: ApplicationFiled: October 25, 2022Publication date: April 13, 2023Inventors: Rimas J. Orentas, Zhongyu Zhu, Crystal L. Mackall, Dimiter S. Dimitrov, Bradley St. Croix, Saurabh Saha
-
Patent number: 11512138Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: GrantFiled: March 18, 2020Date of Patent: November 29, 2022Assignees: The United States of America, as Presented by the Secretary, Department of Health and Human Services, Biomed Valley Discoveries, Inc.Inventors: Rimas J. Orentas, Zhongyu Zhu, Crystal L. Mackall, Dimiter S. Dimitrov, Bradley St. Croix, Saurabh Saha
-
Publication number: 20220315665Abstract: The present disclosure generally relates to, inter alia, antibodies and chimeric antigen receptors (CARs) that bind a Glypican 2 (GPC2) antigen. The disclosure also provides compositions and methods useful for producing such antibodies and CARs, as well as methods for the diagnosis, prevention, and/or treatment of health conditions associated with the GPC2 antigen expression.Type: ApplicationFiled: May 6, 2020Publication date: October 6, 2022Inventors: Sabine HEITZENEDER, Robbie G. MAJZNER, Crystal L. MACKALL, John M. MARIS, Kristopher R. BOSSE, Dimiter S. DIMITROV, Zhongyu ZHU
-
Publication number: 20220218751Abstract: The present disclosure generally relates to, inter alia, novel chimeric polypeptides and chimeric antigen receptors (CARs) that include a hinge domain from CD28 and optionally a costimulatory domain not from CD28. The disclosure also provides compositions and methods useful for producing such molecules, as well as methods for the detection and treatment of diseases, such as cancer.Type: ApplicationFiled: May 6, 2020Publication date: July 14, 2022Inventors: Robbie G. Majzner, Crystal L. Mackall, Louai Labanieh, Skyler P. Rietberg
-
Publication number: 20200283522Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: ApplicationFiled: May 8, 2020Publication date: September 10, 2020Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Rimas J. Orentas, Ira H. Pastan, Dimiter S. Dimitrov, Crystal L. Mackall
-
Publication number: 20200255534Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: ApplicationFiled: March 18, 2020Publication date: August 13, 2020Inventors: Rimas J. Orentas, Zhongyu Zhu, Crystal L. Mackall, Dimiter S. Dimitrov, Bradley St. Croix, Saurabh Saha
-
Patent number: 10738116Abstract: The invention provides dual specific chimeric antigen receptors (CARs) having antigenic specificity for CD19 and CD22. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: GrantFiled: March 18, 2016Date of Patent: August 11, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Terry J. Fry, Crystal L. Mackall, Rimas J. Orentas, Waleed Haso, Haiying Qin
-
Patent number: 10703816Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: GrantFiled: August 21, 2018Date of Patent: July 7, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Rimas J. Orentas, Ira H. Pastan, Dimiter S. Dimitrov, Crystal L. Mackall
-
Publication number: 20200147134Abstract: An embodiment of the invention provides bicistronic chimeric antigen receptor (CAR) amino acid constructs. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CAR constructs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed. Methods of making the CAR constructs are disclosed.Type: ApplicationFiled: May 15, 2018Publication date: May 14, 2020Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Haiying Qin, Crystal L. Mackall, Terry J. Fry
-
Patent number: 10604583Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: GrantFiled: September 8, 2017Date of Patent: March 31, 2020Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Biomed Valley Discoveries, Inc.Inventors: Rimas J. Orentas, Zhongyu Zhu, Crystal L. Mackall, Dimiter S. Dimitrov, Bradley St. Croix, Saurabh Saha
-
Patent number: 10562952Abstract: Chimeric antigen receptors (CARs) that specifically bind to and immunologically recognize CD276 are disclosed. Related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: GrantFiled: September 9, 2016Date of Patent: February 18, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Crystal L. Mackall, Yongzhi Karen Cui
-
Publication number: 20190085078Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: ApplicationFiled: August 21, 2018Publication date: March 21, 2019Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Rimas J. Orentas, Ira H. Pastan, Dimiter S. Dimitrov, Crystal L. Mackall
-
Publication number: 20180346544Abstract: Chimeric antigen receptors (CARs) that specifically bind to and immunologically recognize CD276 are disclosed. Related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: ApplicationFiled: September 9, 2016Publication date: December 6, 2018Inventors: Crystal L. Mackall, Yongzhi Karen Cui